Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET)

被引:85
作者
Flamen, P
Hoekstra, OS
Homans, F
Van Cutsem, E
Maes, A
Stroobants, S
Peeters, M
Penninckx, F
Filez, L
Bleichrodt, RP
Mortelmans, L
机构
[1] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Nucl Med, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Internal Med, B-3000 Louvain, Belgium
[3] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Abdominal Surg, B-3000 Louvain, Belgium
[4] Vrije Univ Amsterdam, Univ Hosp, Dept Nucl Med & Surg Oncol, Amsterdam, Netherlands
关键词
positron emission tomography (PET); colorectal cancer; carcinoembryonic antigen;
D O I
10.1016/S0959-8049(01)00049-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to evaluate the use of positron emission tomography with [F-18]-fluorodeoxyglucose (FDG-PET) ill patients with unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer. 50 consecutive patients with elevated CEA levels and a completely normal (n = 31) or equivocal (n = 19) conventional diagnostic work-up (CDW) were retrospectively selected. All PET images were reviewed with full knowledge of the CDW. The gold standard consisted of histology, or clinical follow-up of more than 1 year. Recurrent disease was established in 56 lesions in 43 patients. On a patient-based analysis, the sensitivity of FDG-PET was 34/43 (79%), and the positive predictive value 34/38 (89%). In 14/50 patients (28%). the FDG-PET findings led to a surgical resection with curative intent. On a lesion-based analysis, FDG-PET detected 42/56 lesions (sensitivity: 75%), the positive predictive value was 79% (42/53). These results demonstrate that FDG-PET can have a clear impact on patient management in patients with an unexplained elevation in CEA levels. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:862 / 869
页数:8
相关论文
共 27 条
[1]  
Bast RC, 1996, J CLIN ONCOL, V14, P2843
[2]   CLINICAL-VALUE OF WHOLE-BODY POSITRON EMISSION TOMOGRAPHY WITH [F-18] FLUORODEOXYGLUCOSE IN RECURRENT COLORECTAL-CANCER [J].
BEETS, G ;
PENNINCKX, F ;
SCHIEPERS, C ;
FILEZ, L ;
MORTELMANS, L ;
KERREMANS, R ;
AERTS, R ;
DEROO, M .
BRITISH JOURNAL OF SURGERY, 1994, 81 (11) :1666-1670
[3]  
Beyer T, 2000, J NUCL MED, V41, P1369
[4]   Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? [J].
Carriquiry, LA ;
Piñeyro, A .
DISEASES OF THE COLON & RECTUM, 1999, 42 (07) :921-929
[5]  
Delbeke D, 1997, J NUCL MED, V38, P1120
[6]   Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil [J].
Findlay, M ;
Young, H ;
Cunningham, D ;
Iveson, A ;
Cronin, B ;
Hickish, T ;
Pratt, B ;
Husband, J ;
Flower, M ;
Ott, R .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :700-708
[7]   Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer [J].
Flamen, P ;
Stroobants, S ;
Van Cutsem, E ;
Dupont, P ;
Bormans, G ;
De Vadder, N ;
Penninckx, F ;
Van Hoe, L ;
Mortelmans, L .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :894-901
[8]  
FLANAGAN F, 1997, ANN SURG, V227, P319
[9]   EXPECTANCY OR PRIMARY CHEMOTHERAPY IN PATIENTS WITH ADVANCED ASYMPTOMATIC COLORECTAL-CANCER - A RANDOMIZED TRIAL [J].
GLIMELIUS, B ;
PAHLMAN, L ;
GRAF, W ;
ADAMI, HO ;
TVEIT, K ;
HANSEN, J ;
LILJEGREN, G ;
DOMELoF, L ;
LJUNGQVIST, U ;
BERGMAN, L ;
ENANDER, LK ;
UNDERSKOG, I ;
SoDERBERG, M ;
JoNSSON, PE ;
HAFSTRoM, L ;
HEUMAN, R ;
ATHLIN, L ;
SASSNER, P ;
SELLSTRoM, H .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :904-911
[10]   Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection [J].
Goldberg, RM ;
Fleming, TR ;
Tangen, CM ;
Moertel, CG ;
Macdonald, JS ;
Haller, DG ;
Laurie, JA .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) :27-+